Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU OTCMKTS:BPMUF NASDAQ:EGRX NASDAQ:GERN NASDAQ:UROV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.08+2.0%$1.86$1.43▼$4.26$208.85M1.62158,448 shs51,037 shsBPMUFBasilea Pharmaceutica$61.34$53.46$47.50▼$61.34$807.85M0.290 shsN/AEGRXEagle Pharmaceuticals$3.74+5.4%$2.35$1.50▼$3.87$48.57M0.838,144 shs7,169 shsGERNGeron$1.34+1.5%$1.43$1.17▼$5.06$853.47M0.6413.03 million shs5.31 million shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-0.97%+4.62%+34.21%-43.96%BPMUFBasilea Pharmaceutica0.00%0.00%+6.31%+20.27%+27.39%EGRXEagle Pharmaceuticals0.00%+18.33%+47.92%+184.00%-41.03%GERNGeron0.00%-7.37%-12.58%0.00%-71.97%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.2441 of 5 stars3.51.00.00.03.70.80.6BPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/AEGRXEagle Pharmaceuticals2.4759 of 5 stars0.03.00.03.90.63.30.0GERNGeron3.4565 of 5 stars3.32.00.01.32.71.70.6UROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00476.92% UpsideBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AGERNGeron 2.60Moderate Buy$4.61244.11% UpsideUROVUrovant Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EGRX, ACIU, BPMUF, GERN, and UROV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$1.005/8/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.505/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M6.73N/AN/A$1.29 per share1.61BPMUFBasilea Pharmaceutica$236.92M3.41$6.85 per share8.96$6.99 per share8.78EGRXEagle Pharmaceuticals$257.55M0.19$9.35 per share0.40N/A∞GERNGeron$116.29M7.34N/AN/A$0.46 per share2.91UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)BPMUFBasilea Pharmaceutica$88.14MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AGERNGeron-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)UROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/ALatest EGRX, ACIU, BPMUF, GERN, and UROV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ACIUAC Immune-$0.18N/AN/AN/A$1.98 millionN/A5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ABPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.531.53BPMUFBasilea Pharmaceutica1.184.854.16EGRXEagle PharmaceuticalsN/AN/AN/AGERNGeron0.447.876.97UROVUrovant SciencesN/A2.912.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%BPMUFBasilea PharmaceuticaN/AEGRXEagle Pharmaceuticals85.36%GERNGeron73.71%UROVUrovant Sciences18.44%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%BPMUFBasilea PharmaceuticaN/AEGRXEagle Pharmaceuticals28.90%GERNGeron7.42%UROVUrovant Sciences2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataGERNGeron70636.92 million589.66 millionOptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableEGRX, ACIU, BPMUF, GERN, and UROV HeadlinesRecent News About These CompaniesRoivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation RiddleJuly 5, 2025 | seekingalpha.comSumitomo brings together Gemtesa 'Go-Getters' to discuss overactive bladder symptomsDecember 4, 2024 | fiercepharma.comFXavier Creative House Appoints Jami Rogers as VP of Sales & MarketingNovember 4, 2024 | msn.comXavier Creative House Hires Jami Rogers as Vice President of Sales & MarketingOctober 29, 2024 | finance.yahoo.comPierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromeApril 26, 2024 | finanznachrichten.dePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromeApril 26, 2024 | finance.yahoo.comOC Drugmakers Cut Headcounts, Close OfficesApril 22, 2024 | ocbj.comOA2 Bio’s new CEO aims to grow platformApril 8, 2024 | pacbiztimes.comPC-Suite Shuffle: A2 Bio, Bayer, BioNTech and MoreMarch 27, 2024 | biospace.comBA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsMarch 26, 2024 | finance.yahoo.comHEALTH BEHAVIOR AND NUTRITION SCIENCESFebruary 17, 2024 | udel.eduUBulletin Science and Security BoardFebruary 15, 2024 | thebulletin.orgTSecretary-General’s Guidance Note on Behavioural ScienceFebruary 5, 2024 | un.orgUMarine Sciences & TechnologyJanuary 7, 2024 | uml.eduUThe 7 Best Science Kits for Kids and TeensDecember 21, 2023 | popularmechanics.comPCareers in Computer ScienceDecember 11, 2023 | mccormick.northwestern.eduMPhD in Information ScienceDecember 8, 2023 | drexel.eduDPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsDecember 6, 2023 | finance.yahoo.comCore Requirements & CoursesDecember 1, 2023 | bc.eduBInspiring Women in ScienceNovember 28, 2023 | nature.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, ACIU, BPMUF, GERN, and UROV Company DescriptionsAC Immune NASDAQ:ACIU$2.08 +0.04 (+1.96%) Closing price 04:00 PM EasternExtended Trading$1.94 -0.14 (-6.68%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Basilea Pharmaceutica OTCMKTS:BPMUF$61.34 0.00 (0.00%) As of 07/11/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Eagle Pharmaceuticals NASDAQ:EGRX$3.74 +0.19 (+5.35%) As of 03:40 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Geron NASDAQ:GERN$1.34 +0.02 (+1.52%) Closing price 04:00 PM EasternExtended Trading$1.33 -0.01 (-0.75%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Urovant Sciences NASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? 3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
